ExodusPoint Capital Management’s Turnstone Biologics TSBX Stock Holding History

ExodusPoint Capital Management’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-454,026	Closed	-$253K	–	2069
2024 Q3	$253K	Sell	454,026 -10,795	-2%	-$16.6K	﹤0.01%	1408
2024 Q2	$1.22M	Buy	464,821 +95,041	+26%	+$272K	0.01%	950
2024 Q1	$969K	Buy	369,780 +102,927	+39%	+$295K	0.01%	958
2023 Q4	$679K	Sell	266,853 -53,846	-17%	-$141K	﹤0.01%	951
2023 Q3	$1.26M	Buy	+320,699	New	+$2.86M	0.01%	870

Other funds holding TSBX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

ExodusPoint Capital Management's TSBX Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Turnstone Biologics (TSBX) in Q4 2024, closing a stake of 454,026 shares — an estimated $253K sold.

ExodusPoint Capital Management first reported a position in TSBX in Q3 2023 and held it in 5 quarters. The position peaked at $1.26M in Q3 2023. 28 funds tracked by Wall St. Rank hold TSBX as of Q4 2024.

ExodusPoint Capital Management reported no remaining Turnstone Biologics position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 454,026 Turnstone Biologics shares in Q4 2024, an estimated $253K.
ExodusPoint Capital Management first reported a position in Turnstone Biologics in Q3 2023 and held it in 5 quarters.
ExodusPoint Capital Management's Turnstone Biologics position peaked at $1.26M in Q3 2023.
28 funds tracked by Wall St. Rank held Turnstone Biologics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.